Disease staging of Alzheimer’s disease using a CSF-based biomarker model
Gemma Salvadó(Lund University), Oskar Hansson(Lund University), Randall J. Bateman(Washington University in St. Louis), Sebastian Palmqvist(Lund University), Rik Ossenkoppele(University of California, Berkeley), Erik Stomrud(Lund University), John C. Morris(Mayo Clinic), Nicolas R. Barthélemy(Washington University in St. Louis), Suzanne E. Schindler(Meharry Medical College), Shorena Janelidze(Lund University), Jacob W. Vogel(University of Pennsylvania), Charles D. Chen(Mallinckrodt (United States)), Kanta Horie(Washington University in St. Louis), Andrew J. Aschenbrenner(Washington University in St. Louis), David M. Holtzman(Hope Center for Neurological Disorders), Tammie L.S. Benzinger(Washington University in St. Louis), Brian A. Gordon(Washington University in St. Louis), Alexa Pichet Binette(Lund University)
Cited by 108
Related Papers
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases
|Immunity|2017|3k
Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature
|Journal of Neuropathology & Experimental Neurology|2012|2.1k
Brain charts for the human lifespan
|Nature|2022|1.8k